Department of General Practice, Erasmus MC University Medical Center, Rotterdam, The Netherlands
Department of General Practice, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
BMJ Open. 2024 May 15;14(5):e078942. doi: 10.1136/bmjopen-2023-078942.
The Rotterdam Eczema Study was an observational cohort study with an embedded pragmatic randomised controlled open-label trial. It was conducted in children with atopic dermatitis (AD) in the Dutch primary care system. The objective of the trial was to determine whether a potent topical corticosteroid (TCS) is more effective than a low-potency TCS.
We are aiming to communicate transparently about the poor recruitment for the trial part and to explore the reasons why recruitment was weak.
We used a survey to find out what patients in the cohort did when they experienced a flare-up.
Descriptive statistics were used to present the baseline characteristics of participants in the trial and the results of the survey.
In total, 367 patients were included in the cohort. Of these, 32 were randomly assigned to a trial treatment; they had a median age of 4.0 years (IQR 2.0-9.8). A total of 69 of the 86 children (80.2%) who could participate in the survey responded. 39 (56.5%) suffered a flare-up during the follow-up (making them potentially eligible for inclusion in the trial). 26 out of 39 (66.7%) increased their use of an emollient and/or TCS themselves. Only 12 of the 39 (30.7%) contacted their general practitioner (GP) as instructed in the study protocol, but 8 out of these 12 did not meet the inclusion criteria for the trial.
The main reason why cohort participants did not take part in the trial was that they did not contact their GPs when they experienced an AD flare-up. Furthermore, the majority of patients who contacted their GPs did not match the inclusion criteria of the trial. We expect that the lessons learnt from this study will be useful when developing future studies of children with AD in primary care.
鹿特丹湿疹研究是一项观察性队列研究,其中嵌入了一项实用随机对照开放标签试验。该研究在荷兰初级保健系统中的特应性皮炎(AD)患儿中进行。该试验的目的是确定强效外用皮质类固醇(TCS)是否比弱效 TCS 更有效。
我们旨在透明地沟通试验部分的招募情况不佳,并探讨招募不力的原因。
我们使用调查来了解队列中的患者在出现发作时会做什么。
描述性统计用于呈现试验参与者的基线特征和调查结果。
共有 367 名患者纳入队列。其中 32 名随机分配到试验治疗组;他们的中位年龄为 4.0 岁(IQR 2.0-9.8)。共有 86 名有资格参加调查的儿童中有 69 名(80.2%)做出了回应。39 名(56.5%)在随访期间出现发作(使他们有资格被纳入试验)。39 名中的 26 名(66.7%)自行增加了保湿剂和/或 TCS 的使用。只有 39 名中的 12 名(30.7%)按照研究方案的指示联系了他们的全科医生(GP),但这 12 名中的 8 名不符合试验纳入标准。
队列参与者未参加试验的主要原因是他们在出现 AD 发作时未联系他们的 GP。此外,大多数联系他们的 GP 的患者不符合试验的纳入标准。我们预计,从这项研究中吸取的经验教训将对未来在初级保健中开展 AD 儿童研究有用。